LymphedemaV1, PubMed, Checkpoint, bibRecord, 002007

Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.

Identifieur interne : 002007 ( PubMed/Checkpoint ); précédent : 002006; suivant : 002008

Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.

Auteurs : Suraj G. Bhansali [États-Unis] ; Sathy V. Balu-Iyer ; Marilyn E. Morris

Source :

Journal of pharmaceutical sciences [ 1520-6017 ] ; 2012.

RBID : pubmed:22030745

Descripteurs français

English descriptors

KwdEn :
- Animals, Area Under Curve, Blood, Chromatography, Thin Layer, Drug Administration Routes, Liposomes, Lymph Nodes, Mice, Microscopy, Electron, Transmission, Recombinant Proteins (administration & dosage), Recombinant Proteins (pharmacology), Vascular Endothelial Growth Factor C (administration & dosage), Vascular Endothelial Growth Factor C (pharmacology).
MESH :
- chemical , administration & dosage : Recombinant Proteins, Vascular Endothelial Growth Factor C.
- chemical , pharmacology : Recombinant Proteins, Vascular Endothelial Growth Factor C.
- chemical : Liposomes.
- Animals, Area Under Curve, Blood, Chromatography, Thin Layer, Drug Administration Routes, Lymph Nodes, Mice, Microscopy, Electron, Transmission.

Abstract

VEGF-C156S is a recombinant form of human vascular endothelial growth factor C (VEGF-C), which targets the receptor VEGFR-3 present in the lymphatics. VEGF-C156S has lymphangiogenic properties and may represent a potential therapeutic approach in treating the lymphatic disease lymphedema. In the present study, we tested the hypotheses that (1) subcutaneous (s.c.) injection will provide higher lymphatic exposure than intravenous (i.v.) administration of VEGF-C156S and (2) s.c. injection of liposomal (s.c. Lipo) VEGF-C156S will provide greater lymphatic exposure than nonliposomal proteins. The protein VEGF-C156S was radiolabeled with Iodine-125 by a modified chloramine-T method and encapsulated into liposomes. The protein was injected at a dose of 125 μg/kg to mice i.v. or s.c.; the liposomal preparation was administered s.c. (s.c. Lipo). Blood and lymph nodes were collected over 24 h. The mean residence time in lymph nodes after s.c. or s.c. (Lipo) administration was approximately double that following i.v. administration. The area under the concentration-time curve (AUC) ratio of lymph node-blood after s.c. administration of VEGF-C156S was more than double of the AUC ratio after i.v. administration. The results suggest that lymph node exposure of VEGF-C156S was significantly higher after s.c. administration of liposomal or nonliposomal protein as compared with i.v. administration.

DOI: 10.1002/jps.22795
PubMed: 22030745

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PubMed, to step Corpus: 002413
to stream PubMed, to step Curation: 002413

Links to Exploration step

pubmed:22030745

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.</title>
<author><name sortKey="Bhansali, Suraj G" sort="Bhansali, Suraj G" uniqKey="Bhansali S" first="Suraj G" last="Bhansali">Suraj G. Bhansali</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260-1200, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260-1200</wicri:regionArea>
<orgName type="university">Université d'État de New York à Buffalo</orgName>
<placeName><settlement type="city">Buffalo (New York)</settlement>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Balu Iyer, Sathy V" sort="Balu Iyer, Sathy V" uniqKey="Balu Iyer S" first="Sathy V" last="Balu-Iyer">Sathy V. Balu-Iyer</name>
</author>
<author><name sortKey="Morris, Marilyn E" sort="Morris, Marilyn E" uniqKey="Morris M" first="Marilyn E" last="Morris">Marilyn E. Morris</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22030745</idno>
<idno type="pmid">22030745</idno>
<idno type="doi">10.1002/jps.22795</idno>
<idno type="wicri:Area/PubMed/Corpus">002413</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002413</idno>
<idno type="wicri:Area/PubMed/Curation">002413</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002413</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002413</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002413</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.</title>
<author><name sortKey="Bhansali, Suraj G" sort="Bhansali, Suraj G" uniqKey="Bhansali S" first="Suraj G" last="Bhansali">Suraj G. Bhansali</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260-1200, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260-1200</wicri:regionArea>
<orgName type="university">Université d'État de New York à Buffalo</orgName>
<placeName><settlement type="city">Buffalo (New York)</settlement>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Balu Iyer, Sathy V" sort="Balu Iyer, Sathy V" uniqKey="Balu Iyer S" first="Sathy V" last="Balu-Iyer">Sathy V. Balu-Iyer</name>
</author>
<author><name sortKey="Morris, Marilyn E" sort="Morris, Marilyn E" uniqKey="Morris M" first="Marilyn E" last="Morris">Marilyn E. Morris</name>
</author>
</analytic>
<series><title level="j">Journal of pharmaceutical sciences</title>
<idno type="eISSN">1520-6017</idno>
<imprint><date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Area Under Curve</term>
<term>Blood</term>
<term>Chromatography, Thin Layer</term>
<term>Drug Administration Routes</term>
<term>Liposomes</term>
<term>Lymph Nodes</term>
<term>Mice</term>
<term>Microscopy, Electron, Transmission</term>
<term>Recombinant Proteins (administration & dosage)</term>
<term>Recombinant Proteins (pharmacology)</term>
<term>Vascular Endothelial Growth Factor C (administration & dosage)</term>
<term>Vascular Endothelial Growth Factor C (pharmacology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Aire sous la courbe</term>
<term>Animaux</term>
<term>Chromatographie sur couche mince</term>
<term>Facteur de croissance endothéliale vasculaire de type C (administration et posologie)</term>
<term>Facteur de croissance endothéliale vasculaire de type C (pharmacologie)</term>
<term>Liposomes</term>
<term>Microscopie électronique à transmission</term>
<term>Noeuds lymphatiques</term>
<term>Protéines recombinantes (administration et posologie)</term>
<term>Protéines recombinantes (pharmacologie)</term>
<term>Sang</term>
<term>Souris</term>
<term>Voies d'administration de substances chimiques et des médicaments</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Recombinant Proteins</term>
<term>Vascular Endothelial Growth Factor C</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Recombinant Proteins</term>
<term>Vascular Endothelial Growth Factor C</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Liposomes</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type C</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Facteur de croissance endothéliale vasculaire de type C</term>
<term>Protéines recombinantes</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Area Under Curve</term>
<term>Blood</term>
<term>Chromatography, Thin Layer</term>
<term>Drug Administration Routes</term>
<term>Lymph Nodes</term>
<term>Mice</term>
<term>Microscopy, Electron, Transmission</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Aire sous la courbe</term>
<term>Animaux</term>
<term>Chromatographie sur couche mince</term>
<term>Liposomes</term>
<term>Microscopie électronique à transmission</term>
<term>Noeuds lymphatiques</term>
<term>Sang</term>
<term>Souris</term>
<term>Voies d'administration de substances chimiques et des médicaments</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">VEGF-C156S is a recombinant form of human vascular endothelial growth factor C (VEGF-C), which targets the receptor VEGFR-3 present in the lymphatics. VEGF-C156S has lymphangiogenic properties and may represent a potential therapeutic approach in treating the lymphatic disease lymphedema. In the present study, we tested the hypotheses that (1) subcutaneous (s.c.) injection will provide higher lymphatic exposure than intravenous (i.v.) administration of VEGF-C156S and (2) s.c. injection of liposomal (s.c. Lipo) VEGF-C156S will provide greater lymphatic exposure than nonliposomal proteins. The protein VEGF-C156S was radiolabeled with Iodine-125 by a modified chloramine-T method and encapsulated into liposomes. The protein was injected at a dose of 125 μg/kg to mice i.v. or s.c.; the liposomal preparation was administered s.c. (s.c. Lipo). Blood and lymph nodes were collected over 24 h. The mean residence time in lymph nodes after s.c. or s.c. (Lipo) administration was approximately double that following i.v. administration. The area under the concentration-time curve (AUC) ratio of lymph node-blood after s.c. administration of VEGF-C156S was more than double of the AUC ratio after i.v. administration. The results suggest that lymph node exposure of VEGF-C156S was significantly higher after s.c. administration of liposomal or nonliposomal protein as compared with i.v. administration.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22030745</PMID>
<DateCreated><Year>2012</Year>
<Month>01</Month>
<Day>03</Day>
</DateCreated>
<DateCompleted><Year>2012</Year>
<Month>05</Month>
<Day>11</Day>
</DateCompleted>
<DateRevised><Year>2012</Year>
<Month>01</Month>
<Day>03</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6017</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>101</Volume>
<Issue>2</Issue>
<PubDate><Year>2012</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Journal of pharmaceutical sciences</Title>
<ISOAbbreviation>J Pharm Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.</ArticleTitle>
<Pagination><MedlinePgn>852-9</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/jps.22795</ELocationID>
<Abstract><AbstractText>VEGF-C156S is a recombinant form of human vascular endothelial growth factor C (VEGF-C), which targets the receptor VEGFR-3 present in the lymphatics. VEGF-C156S has lymphangiogenic properties and may represent a potential therapeutic approach in treating the lymphatic disease lymphedema. In the present study, we tested the hypotheses that (1) subcutaneous (s.c.) injection will provide higher lymphatic exposure than intravenous (i.v.) administration of VEGF-C156S and (2) s.c. injection of liposomal (s.c. Lipo) VEGF-C156S will provide greater lymphatic exposure than nonliposomal proteins. The protein VEGF-C156S was radiolabeled with Iodine-125 by a modified chloramine-T method and encapsulated into liposomes. The protein was injected at a dose of 125 μg/kg to mice i.v. or s.c.; the liposomal preparation was administered s.c. (s.c. Lipo). Blood and lymph nodes were collected over 24 h. The mean residence time in lymph nodes after s.c. or s.c. (Lipo) administration was approximately double that following i.v. administration. The area under the concentration-time curve (AUC) ratio of lymph node-blood after s.c. administration of VEGF-C156S was more than double of the AUC ratio after i.v. administration. The results suggest that lymph node exposure of VEGF-C156S was significantly higher after s.c. administration of liposomal or nonliposomal protein as compared with i.v. administration.</AbstractText>
<CopyrightInformation>Copyright © 2011 Wiley Periodicals, Inc.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bhansali</LastName>
<ForeName>Suraj G</ForeName>
<Initials>SG</Initials>
<AffiliationInfo><Affiliation>Department of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260-1200, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Balu-Iyer</LastName>
<ForeName>Sathy V</ForeName>
<Initials>SV</Initials>
</Author>
<Author ValidYN="Y"><LastName>Morris</LastName>
<ForeName>Marilyn E</ForeName>
<Initials>ME</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2011</Year>
<Month>10</Month>
<Day>26</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>J Pharm Sci</MedlineTA>
<NlmUniqueID>2985195R</NlmUniqueID>
<ISSNLinking>0022-3549</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D008081">Liposomes</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011994">Recombinant Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C467486">VEGFC protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D042582">Vascular Endothelial Growth Factor C</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001769" MajorTopicYN="Y">Blood</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002855" MajorTopicYN="N">Chromatography, Thin Layer</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004333" MajorTopicYN="N">Drug Administration Routes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008081" MajorTopicYN="Y">Liposomes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008198" MajorTopicYN="Y">Lymph Nodes</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046529" MajorTopicYN="N">Microscopy, Electron, Transmission</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011994" MajorTopicYN="N">Recombinant Proteins</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D042582" MajorTopicYN="N">Vascular Endothelial Growth Factor C</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year>
<Month>07</Month>
<Day>01</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2011</Year>
<Month>09</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2011</Year>
<Month>10</Month>
<Day>04</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2011</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2011</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2012</Year>
<Month>5</Month>
<Day>12</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">22030745</ArticleId>
<ArticleId IdType="doi">10.1002/jps.22795</ArticleId>
<ArticleId IdType="pii">S0022-3549(15)31723-8</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>État de New York</li>
</region>
<settlement><li>Buffalo (New York)</li>
</settlement>
<orgName><li>Université d'État de New York à Buffalo</li>
</orgName>
</list>
<tree><noCountry><name sortKey="Balu Iyer, Sathy V" sort="Balu Iyer, Sathy V" uniqKey="Balu Iyer S" first="Sathy V" last="Balu-Iyer">Sathy V. Balu-Iyer</name>
<name sortKey="Morris, Marilyn E" sort="Morris, Marilyn E" uniqKey="Morris M" first="Marilyn E" last="Morris">Marilyn E. Morris</name>
</noCountry>
<country name="États-Unis"><region name="État de New York"><name sortKey="Bhansali, Suraj G" sort="Bhansali, Suraj G" uniqKey="Bhansali S" first="Suraj G" last="Bhansali">Suraj G. Bhansali</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002007 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002007 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    RBID
   |clé=     pubmed:22030745
   |texte=   Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i   -Sk "pubmed:22030745" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024

	Serveur d'exploration sur le lymphœdème
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le lymphœdème

Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.

Influence of route of administration and liposomal encapsulation on blood and lymph node exposure to the protein VEGF-C156S.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki